Key result
Ivabradine, trimetazidine, and intravenous iron are the only pharmacological interventions in the ESC guidelines consistently shown to improve functional capacity and quality of life in heart failure.
Why the study?
Do pharmacological interventions such as ivabradine, trimetazidine, and intravenous iron improve exercise capacity and quality of life in patients with heart failure?
Do pharmacological interventions such as ivabradine, trimetazidine, and intravenous iron improve exercise capacity and quality of life in patients with heart failure?
Ivabradine, trimetazidine, and intravenous iron are highlighted as key guideline-supported pharmacological interventions that improve exercise capacity and quality of life in heart failure patients.
May prioritize these agents for functional and QoL gains in HF; leaves open whether alternatives merit guideline inclusion.
Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.
No takes yet. Share an insight, caveat, or question.
Vitale et al. (2018) conducted a review in Heart failure. Pharmacological interventions (Ivabradine, trimetazidine, and intravenous iron) was evaluated on Exercise capacity. Ivabradine, trimetazidine, and intravenous iron are the only pharmacological interventions in the ESC guidelines consistently shown to improve functional capacity and quality of life in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: